Long-term investors need to learn to stomach the ride.
News & Analysis: BioMarin Pharmaceutical
BMRN earnings call for the period ending June 30, 2019.
Here's why this team of biotech experts are giddy about these stocks right now.
If you have some cash to put to work, you'll want to take a look at these three companies from the tech, drug, and industrial sectors.
The latest trial results for its hemophilia A gene therapy suggest it may eliminate or significantly reduce the need for weekly infusions.
Global Payments and Total Systems Services announced they plan to merge, and BioMarin reported results from a gene therapy trial.
There's at least one thing about these biotechs that the Oracle of Omaha should find especially appealing.
Despite the biotech's move into gene therapy, its bread and butter are still paying the bills.
BMRN earnings call for the period ending March 31, 2019.
BioMarin, Waste Management, and Walmart are three top defensive picks worth buying now.